Evidence map›Paper›PMID 21859946›Full record

ArticleAntimicrobial agents and chemotherapy2011

Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.

Jason A Rosenzweig, Sheri M Brackman, Michelle L Kirtley, Jian Sha, Tatiana E Erova, Linsey A Yeager, Johnny W Peterson, Ze-Qi Xu, Ashok K Chopra

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Carbohydrate-based drugs launched during 2000Acta pharmaceutica Sinica. B · 2022
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jason A RosenzweigDepartment of Biology, Center for Bionanotechnology and Environmental Research, Texas Southern University, 3100 Cleburne Street, Houston, Texas 77555-1070, USA.
Sheri M Brackman
Michelle L Kirtley
Jian Sha
Tatiana E Erova
Linsey A Yeager
Johnny W Peterson
Ze-Qi Xu
Ashok K Chopra
The University of Texas Medical Branch at Galveston · USTexas Southern University · US

Funding

Task 7 (C29): Development of a Small Animal Model for Dengue N01AI30065 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · 2007 to 2009
$11.1M
Identification of New Antigens for a Plague VaccineR01AI064389 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI CHOPRA, ASHOK K · 2005 to 2015
$3.8M
NIAID NIH HHS AI064389NIAID NIH HHS N01 AI030065NIAID NIH HHS N01 AI30065NIAID NIH HHS R01 AI064389
6 · The paper itself

Abstract

The Gram-negative plague bacterium, Yersinia pestis, has historically been regarded as one of the deadliest pathogens known to mankind, having caused three major pandemics. After being transmitted by the bite of an infected flea arthropod vector, Y. pestis can cause three forms of human plague: bubonic, septicemic, and pneumonic, with the latter two having very high mortality rates. With increased threats of bioterrorism, it is likely that a multidrug-resistant Y. pestis strain would be employed, and, as such, conventional antibiotics typically used to treat Y. pestis (e.g., streptomycin, tetracycline, and gentamicin) would be ineffective. In this study, cethromycin (a ketolide antibiotic which inhibits bacterial protein synthesis and is currently in clinical trials for respiratory tract infections) was evaluated for antiplague activity in a rat model of pneumonic infection and compared with levofloxacin, which operates via inhibition of bacterial topoisomerase and DNA gyrase. Following a respiratory challenge of 24 to 30 times the 50% lethal dose of the highly virulent Y. pestis CO92 strain, 70 mg of cethromycin per kg of body weight (orally administered twice daily 24 h postinfection for a period of 7 days) provided complete protection to animals against mortality without any toxic effects. Further, no detectable plague bacilli were cultured from infected animals' blood and spleens following cethromycin treatment. The antibiotic was most effective when administered to rats 24 h postinfection, as the animals succumbed to infection if treatment was further delayed. All cethromycin-treated survivors tolerated 2 subsequent exposures to even higher lethal Y. pestis doses without further antibiotic treatment, which was related, in part, to the development of specific antibodies to the capsular and low-calcium-response V antigens of Y. pestis. These data demonstrate that cethromycin is a potent antiplague drug that can be used to treat pneumonic plague.

Indexed as

LevofloxacinAnimalsAnti-Bacterial AgentsFemaleKetolidesOfloxacinPlagueRatsYersinia pestisAnti-Bacterial AgentscethromycinKetolidesLevofloxacinOfloxacin

Identifiers

PMID21859946
PMCPMC3195012
OpenAlexW1984313231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.